NADAC Survey: What is It and Do I Need to Respond?
Pharmacies that receive a National Average Drug Acquisition Cost (NADAC) Survey frequently contact PAAS National® for information and guidance.
Entries by Dana Westberg, CPhT
When Are Final Audit Results Not Final?
Receiving audit results with discrepancies and financial recoupments can be very discouraging. PAAS National® analysts are here to assist you through the appeal process. Audit results do not always provide all appeal options, and you don’t want to miss out on another chance if your initial appeal is denied.
Caution with Script Care Audits
PAAS National® has seen a rise in desk audits from Script Care.
Auditors Crack Down on Pharmacies That Bypass Plan Limits
PAAS National® analysts want to warn pharmacies about an uptick in PBMs flagging prescriptions for bypassing plan limit rejects.
Remember to Maintain and Provide Complete Clinical Notes!
Pharmacies must be very diligent with electronic documentation when electronically storing their prescriptions.
Dispense in Original Container – Know the Audit Risks
PAAS National® analysts want to remind pharmacies of the audit risks when medications are dispensed outside manufacturer storage/dispensing requirements.
Humana Provides Update on GLP-1 Prescriptions
PAAS National® has recently become aware of an update Humana published regarding new point-of-sale edits for specific medications.
Audit Risks with Schedule II Laddered Prescriptions
Pharmacies receiving laddered Schedule II prescriptions must be aware of the DEA requirements and potential audit risks. Missing these requirements can lead to Federal law violations and PBM audit recoupment.
Ozempic® Package Size Change
All strengths of Ozempic® now come in 3 mL pens. Pharmacies have frequently asked how this change affects patients’ current prescriptions.
Nuances of Insulin Pens and How They May Differ
Priming insulin pens prior to use helps ensure the appropriate dose is being administered.
